[Cefixime in urinary tract infections in women]

Urinary tract infections (UTIs) remain one of the most common bacterial infections in outpatient practice, particularly among women of reproductive age and pregnant patients. One of the therapeutic options for UTIs is cefixime, a broad-spectrum third-generation cephalosporin. Cefixime demonstrates high antimicrobial activity with a minimal number of adverse effects, which explains the absence of contraindications for its use during pregnancy. Cefixime has high oral bioavailability, is often resistant to -lactamases, and ensures sufficient urinary concentration when administered at 400 mg once daily. Pharmacokinetic parameters remain stable during pregnancy, while preclinical studies indicate extremely low penetration into fetal tissues and breast milk (<1% of the dose). The dispersible formulation Cefixime EXPRESS provides additional benefits for pregnant women due to ease of administration, improved tolerability and adherence. Cefixime EXPRESS in dispersible form represents a modern drug for the treatment of both acute uncomplicated cystitis and acute uncomplicated pyelonephritis, particularly in outpatient settings. It combines proven efficacy with convenient dosing, good tolerability, and a rapid clinical response, making it a reasonable treatment choice, especially when first-line drugs are contraindicated or in cases of resistance to other antibiotics.